Yustein Lab

Translational Research lab focusing on understanding the biology and improving therapy for #Osteosarcoma, #Ewing Sarcoma and #Rhabdomyosarcoma 🎗

[JCI insight @JCI_insight]

MYC regulates CSF1 expression via microRNA 17/20a to modulate tumor-associated macrophages in osteosarcoma: https://t.co/HoWKUNT9nJ
@YusteinLab @EmoryMedicine
#Oncology

[Yustein Lab @YusteinLab]

I was honored to present the 2023 AACR-St Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research to Olivier Delattre.

[Yustein Lab @YusteinLab]

@ATLPedsHemOnc @WinshipAtEmory @childrensatl @AgentsMIB Thank you!

[Aflac Cancer and Blood Disorders Center @ATLPedsHemOnc]

Congratulations to Dr. Jason Yustein (@YusteinLab) with @WinshipAtEmory and @childrensatl for his $100,000 research grant through @AgentsMIB to study pediatric osteosarcoma

[Frontiers - Immunology @FrontImmunol]

New Research: Single-cell RNA datasets and bulk RNA datasets analysis demonstrated C1Q+ tumor-associated macrophage as a major and antitumor immune cell population in osteosarcoma: Background

Osteosarcoma is the most frequent primary bone… https://t.co/Pji8ebMHad #immunology

[Francesca Taraballi, Ph.D. (she/her) @TaraballiPhD]

Here we are:
@fede_giordano89 and @GENETICA75 made this happened, together with the support of a lot of others folks (cannot tag all) in collaboration with @YusteinLab https://t.co/aff1AHHUZx

[Winship Cancer Institute of Emory University @WinshipAtEmory]

Winship investigator Jason Yustein, MD, PhD, will receive a grant from the Osteosarcoma Institute (@OSInstitute) in support of his research using combination therapies to improve immune-mediated approaches for high-risk osteosarcoma. ➡️ https://t.co/gr5AN7PV0h

[Bone Cancer Research Trust @BCRT]

During this year's #BoneCancerAwarenessWeek we held our third annual Ewing sarcoma research meeting 🔬🧬 Together with @CwC_UK we brought 100 delegates together to accelerate desperately needed research into Ewing sarcoma 👉 https://t.co/lmEAENqR07 #Research #UntilTheresACure

[TCH Pediatric Hematology Oncology Fellowship @TCHHemOncFellow]

The @TexasChildrens O'Quinn Medical Tower and the fountains at Texas Children's Hospital West Campus and The Woodlands were lit up gold in recognition of #ChildhoodCancerAwarenessMonth! Join us in raising awareness during the month of September

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

🔬Dr. Jason Yustein discussed his research - evaluating combination therapies to improve immune-mediated approaches for osteosarcoma.

💬Watch the full episode here or listen where you podcast! https://t.co/dHP5H9FpXC

✨This episode is sponsored by our friends at @osinstitute.

[Cancers MDPI @Cancers_MDPI]

🔊Today we share #Review "Recent Insights into Therapy Resistance in #Osteosarcoma"

👏by @ZPrudowskyMD and Jason T. Yustein @YusteinLab @bcmhouston @TexasChildrens

Access the paper here👉https://t.co/68Xzj0SEdN

Keywords: osteosarcoma; chemotherapy resistance

[Yustein Lab @YusteinLab]

@AgentsMIB @CUSystem @ChildrensColo @ColoradoStateU @EmoryUniversity Grateful and honored! 🎗
Thanks @AgentsMIB

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

👏MIB Agents is awarding six OutSmarting Osteosarcoma grants totaling $450,000 in 2022!

📰For the full press release on these exciting awards and FACTOR: https://t.co/FLuxl3piJv

#outsmartingosteosarcoma #osteosarcoma #osteosarcomaresearchgrant #researchgrant #becauseofyou

[Frontiers - Immunology @FrontImmunol]

New Research: Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications: Osteosarcoma is a primary malignant tumor that tends to threaten children and adolescents, and the 5-year event-free survival… https://t.co/FpxXMUlcWS #immunology

[MIB Agents Osteosarcoma Alliance @AgentsMIB]

😁FACTOR22PANEL: Liquid Biopsies & Biomarkers

👉Discussing what we can learn from osteosarcoma blood & tissue samples including best practices for optimizing & allocating tissue samples, & the latest on liquid biopsies for osteosarcoma.

https://t.co/WqoY0lKIRl

[Rein in Sarcoma @reininsarcoma]

John’s journey with Ewing's Sarcoma began with back pain, and tingling and numbness in his leg. He went through grueling treatment; unfortunately, John’s passed away on June 8th, 2019.

His family established the John Phillip Douglass Fund. Story/donate : https://t.co/2Y0SxfjWwF

[DMM Journal @DMM_Journal]

#EditorsChoice from our RAS pathway special issue is @YusteinLab's paper characterising advanced 🐁 model of paediatric #sarcoma that can enable development of novel therapies

Chosen by guest Editors @DarArvin @bradylabupenn
💡https://t.co/XljMp4j6po
📰https://t.co/r9mcbMR9Tc

[Yustein Lab @YusteinLab]

Happy to share our new publication on RMS!
K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications https://t.co/k5vhuywEj2

[Yustein Lab @YusteinLab]

Celebrating Faris’ birthday and the 3-year anniversary of the Faris Foundation today!

[The Faris Foundation @FarisFoundation]

OMG! The Faris Foundation Turns 3! - https://t.co/0v4oRPcc6l